US tissue implants sector holds firm over CryoLife revelations
This article was originally published in Clinica
Executive Summary
In a brief passage of events that will have done little to strengthen public faith in the tissue implants industry, US tissue preserver and processor CryoLife last week admitted that an infection had developed in a patient who had been implanted with one of its cryopreserved human heart valves, thereby appearing to backtrack on claims it made in June.